Zentiva Successfully Completes Its Voluntary Public Tender Offer for APONTIS PHARMA AG

Zentiva Concludes Its Tender Offer for APONTIS PHARMA AG

Zentiva AG, a fully-owned subsidiary of Zentiva Pharma GmbH based in Frankfurt am Main, has successfully completed its voluntary public tender offer for APONTIS PHARMA AG. This strategic acquisition sees Zentiva gaining approximately 83.57% of the capital shares and about 85.27% of voting rights in APONTIS PHARMA.

The culmination of this tender offer was officially announced on December 9, 2024, marking a significant milestone for Zentiva as it strengthens its position in the pharmaceutical market. This move follows the announcement made on November 27, 2024, where all conditions set forth in the offer document were met or effectively waived by Zentiva.

Upon settling the offer, Zentiva and APONTIS PHARMA have mutually agreed to halt the public trading of APONTIS PHARMA's shares in the open market immediately thereafter, following compliance with legal requirements. Consequently, a separate delisting offer will not be necessary. The acceptance period for Zentiva’s tender offer has now expired, and shareholders of APONTIS PHARMA wishing to sell their shares can reach out to the designated contact for assistance.

For additional information regarding this public tender offer, interested parties can visit the official website at Zentiva Offer.

Overview of Zentiva

Zentiva is a premier platform operating across Europe, focused on the development, manufacturing, and provision of affordable, high-quality medications to over 100 million individuals in the region. The company boasts four fully-owned manufacturing plants and a robust network of external manufacturing partners to ensure a secure supply chain. Their solutions span critical therapeutic areas, including cardiology, endocrinology, oncology, respiratory health, and central nervous system disorders, alongside an expansion of their self-care portfolio.

Operating under private equity ownership, Zentiva is aiming for a sustainable double-digit growth trajectory with an ambitious five-year plan set in place for further solid growth, both organically and inorganically, throughout Europe. The company is backed by a team of nearly 5,000 dedicated professionals who share a common commitment to enhancing health and wellness across generations. They strive to create a workplace where each individual feels included, valued, and empowered to contribute to their fullest potential.

Insights on APONTIS PHARMA

APONTIS PHARMA stands out in the pharmaceutical landscape as a leader specializing in single pill combinations in Germany. These innovative single pills amalgamate two to three generic active ingredients into a solitary dosing form taken once daily. Scientific studies have substantiated that therapies employing single-pill combinations significantly boost adherence, thus enhancing treatment outcomes and patient quality of life while concurrently lowering complications, mortality rates, and treatment costs.

As a result, these single pill combinations are regarded as a preferred treatment option in numerous international treatment guidelines, including those in the EU and Germany. Since its inception in 2013, APONTIS PHARMA has been actively developing, promoting, and distributing a broad portfolio of single pill combinations and various pharmaceutical products, particularly aimed at addressing cardiovascular diseases, such as hypertension and hyperlipidemia.

Further details regarding APONTIS PHARMA can be found at their official site APONTIS PHARMA.

Important Notice

It is essential to understand that this announcement is not a purchase offer nor does it solicit the sale of APONTIS PHARMA shares or any other securities. The public tender offer should only be regarded in connection with the offer document published on October 24, 2024, and modified on November 19, 2024. Interested investors and APONTIS PHARMA shareholders are encouraged to carefully read the modified offer document and other pertinent materials related to the offer, as they encompass significant information relevant to the offer.

In summary, this acquisition marks a momentous occasion for Zentiva as it seeks to leverage the strengths of APONTIS PHARMA to further its mission of delivering quality, affordable pharmaceutical solutions to the market.